Antiplatelet medications remain a cornerstone of therapy for atherosclerotic cardiovascular
and cerebrovascular diseases. In primary prevention (patients with cardiovascular risk …

Recurrent atherothrombotic events in patients with acute coronary syndromes (ACS) and/or
those undergoing percutaneous coronary intervention (PCI) are essentially platelet‐driven …

Aspirin is the foundation antiplatelet therapy for patients at risk of cardiovascular events. The
thienopyridine, clopidogrel, is modestly more effective than aspirin and in patients with …

The current standard care for acute coronary syndromes is dual antiplatelet therapy
combining the COX1 inhibitor aspirin with a drug targeting the P2Y12 receptor, together with …

Atherosclerosis is a chronic inflammatory process that is known to be the underlying cause
of coronary artery disease (CAD). 1 In addition to being the first step of primary hemostasis …

Clinical presentations of atherothrombotic vascular disease, such as acute coronary
syndromes, ischemic stroke or transient ischemic attack, and symptomatic peripheral arterial …

Antiplatelet agents are the cornerstone of treatment for patients with acute coronary
syndromes and patients undergoing percutaneous coronary intervention. The current “gold …

Platelet-mediated thrombosis is a major pathophysiological mechanism that underlies acute
coronary syndromes, and therefore, antiplatelet therapy is an important foundation in the …

Antiplatelet drugs are important components in the management of atherothrombotic
vascular disease. However, several limitations restrict the safety and efficacy of current …

Aims To describe outcomes of patients with chronic coronary artery disease (CAD) and/or
peripheral artery disease (PAD) enrolled in the Cardiovascular Outcomes for People Using …